Stryker (NYSE:SYK) had its price target upped by equities researchers at Leerink Swann from $177.00 to $184.00 in a research report issued on Wednesday. The firm presently has an “outperform” rating on the medical technology company’s stock. Leerink Swann’s price target points to a potential upside of 11.52% from the company’s previous close.
Several other analysts have also recently commented on the stock. JPMorgan Chase & Co. upgraded shares of Stryker from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $161.00 to $173.00 in a report on Thursday, November 16th. BMO Capital Markets upgraded shares of Stryker to a “market perform” rating and set a $163.00 price target for the company in a report on Tuesday, December 12th. Zacks Investment Research cut shares of Stryker from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, SunTrust Banks restated a “buy” rating and set a $161.00 price target on shares of Stryker in a report on Friday, November 17th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $159.85.
Shares of Stryker (SYK) traded down $3.45 on Wednesday, hitting $165.00. 662,340 shares of the company’s stock traded hands, compared to its average volume of 1,244,731. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. The firm has a market capitalization of $63,152.60, a PE ratio of 35.26, a price-to-earnings-growth ratio of 2.42 and a beta of 0.78. Stryker has a one year low of $121.86 and a one year high of $170.00.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.40% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of SYK. Acrospire Investment Management LLC bought a new position in shares of Stryker in the second quarter valued at approximately $111,000. Sawyer & Company Inc bought a new position in shares of Stryker in the fourth quarter valued at approximately $125,000. Sit Investment Associates Inc. raised its position in shares of Stryker by 114.3% in the fourth quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares during the period. Oak Point Wealth Management bought a new position in shares of Stryker in the fourth quarter valued at approximately $145,000. Finally, San Francisco Sentry Investment Group CA raised its position in shares of Stryker by 47.8% in the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares during the period. Hedge funds and other institutional investors own 74.94% of the company’s stock.
About Stryker
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.